A California appeals court overturns the preemption of a product liability lawsuit filed against Medtronic over its controversial InFuse bone-growth protein. A California appeals court this week reanimated a product liability lawsuit filed over Medtronic's (NYSE:MDT) controversial InFuse bone-growth protein, reversing a lower court's decision that federal regulations in this case preempt state rules. The preemption doctrine is based on a U.S. Supreme Court ruling that state laws that differ from or add to federal regulations are trumped by the federal rules.
Help employers find you! Check out all the jobs and post your resume.
